Korean Post-marketing Surveillance for Xeljanz XR (Registered)
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms XRPMS
- Sponsors Pfizer
- 19 Mar 2024 Planned End Date changed from 30 Jun 2024 to 6 Dec 2026.
- 19 Mar 2024 Planned primary completion date changed from 30 Jun 2024 to 6 Dec 2026.
- 22 Jan 2024 Planned End Date changed from 31 May 2025 to 30 Jun 2024.